Glenmede Trust’s AbbVie ABBV Stock Holding History

Glenmede Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$74.2M	Sell	341,137 -3,885	-1%	-$862K	0.36%	61
2025 Q4	$78.8M	Buy	+345,022	New	+$78.6M	0.37%	58
2025 Q1	$76M	Buy	362,697 +3,426	+1%	+$666K	0.41%	55
2024 Q4	$63.8M	Sell	359,271 -101,568	-22%	-$18.7M	0.33%	75
2024 Q3	$91M	Sell	460,839 -1,361	-0.3%	-$254K	0.44%	52
2024 Q2	$79.3M	Sell	462,200 -3,419	-0.7%	-$566K	0.4%	57
2024 Q1	$84.8M	Sell	465,619 -100,887	-18%	-$17.4M	0.43%	54
2023 Q4	$87.8M	Buy	566,506 +120,563	+27%	+$17.6M	0.46%	48
2023 Q3	$66.5M	Buy	445,943 +16,850	+4%	+$2.47M	0.38%	66
2023 Q2	$68.4M	Hold	429,093	–	–	0.39%	67
2023 Q1	$68.4M	Sell	429,093 -4,089	-0.9%	-$625K	0.39%	67
2022 Q4	$70M	Sell	433,182 -13,444	-3%	-$2.06M	0.41%	65
2022 Q3	$59.9M	Buy	446,626 +2,417	+0.5%	+$347K	0.38%	69
2022 Q2	$68M	Sell	444,209 -4,897	-1%	-$748K	0.4%	66
2022 Q1	$72.8M	Sell	449,106 -6,322	-1%	-$918K	0.36%	71
2021 Q4	$61.7M	Sell	455,428 -12,133	-3%	-$1.43M	0.29%	90
2021 Q3	$50.4M	Sell	467,561 -4,032	-0.9%	-$461K	0.26%	99
2021 Q2	$53.1M	Sell	471,593 -9,092	-2%	-$1.02M	0.27%	93
2021 Q1	$52M	Sell	480,685 -1,386	-0.3%	-$148K	0.28%	94
2020 Q4	$51.7M	Sell	482,071 -28,471	-6%	-$2.74M	0.28%	98
2020 Q3	$44.7M	Sell	510,542 -537,348	-51%	-$50.6M	0.27%	99
2020 Q2	$103M	Buy	1,047,890 +483,003	+86%	+$42.5M	0.63%	36
2020 Q1	$50M	Hold	564,887	–	–	0.23%	120
2019 Q4	$50M	Sell	564,887 -5,333	-0.9%	-$443K	0.23%	120
2019 Q3	$43.2K	Sell	570,220 -11,211	-2%	-$769K	0.2%	138
2019 Q2	$42.3K	Sell	581,431 -567,586	-49%	-$44.6M	0.19%	150
2019 Q1	$92.6K	Sell	1,149,017 -8,188	-0.7%	-$670K	0.42%	55
2018 Q4	$107K	Buy	1,157,205 +32,100	+3%	+$2.82M	0.52%	43
2018 Q3	$106M	Sell	1,125,105 -581,419	-34%	-$55.1M	0.43%	48
2018 Q2	$158M	Buy	1,706,524 +40,805	+2%	+$3.99M	0.7%	23
2018 Q1	$161M	Hold	1,665,719	–	–	0.67%	24
2017 Q4	$161M	Buy	1,665,719 +464,650	+39%	+$43.8M	0.67%	24
2017 Q3	$107M	Sell	1,201,069 -78,912	-6%	-$6.01M	0.47%	50
2017 Q2	$83.4M	Hold	1,279,981	–	–	0.4%	57
2017 Q1	$83.4M	Sell	1,279,981 -39,891	-3%	-$2.51M	0.4%	57
2016 Q4	$82.6M	Sell	1,319,872 -27,593	-2%	-$1.68M	0.45%	49
2016 Q3	$85M	Sell	1,347,465 -72,265	-5%	-$4.68M	0.48%	43
2016 Q2	$87.9M	Buy	1,419,730 +34,419	+2%	+$2.1M	0.53%	29
2016 Q1	$79.1M	Buy	1,385,311 +365,960	+36%	+$20.4M	0.51%	33
2015 Q4	$60.4M	Sell	1,019,351 -19,508	-2%	-$1.12M	0.41%	57
2015 Q3	$56.5M	Sell	1,038,859 -15,319	-1%	-$997K	0.41%	53
2015 Q2	$70.8M	Sell	1,054,178 -29,011	-3%	-$1.89M	0.51%	36
2015 Q1	$63.4M	Sell	1,083,189 -98,786	-8%	-$5.97M	0.46%	37
2014 Q4	$77.3M	Buy	1,181,975 +121,149	+11%	+$7.64M	0.61%	25
2014 Q3	$61.3M	Buy	1,060,826 +56,898	+6%	+$3.16M	0.54%	33
2014 Q2	$56.7M	Sell	1,003,928 -10,134	-1%	-$532K	0.51%	39
2014 Q1	$52.1M	Sell	1,014,062 -102,201	-9%	-$5.17M	0.48%	47
2013 Q4	$58.9M	Sell	1,116,263 -54,673	-5%	-$2.69M	0.6%	34
2013 Q3	$52.4M	Sell	1,170,936 -48,848	-4%	-$2.17M	0.62%	35
2013 Q2	$50.4M	Buy	+1,219,784	New	+$53.3M	0.63%	36

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Trust's ABBV Position: Q1 2026 in Review

Glenmede Trust reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $862K and leaving 341,137 shares worth $74.2M. The position accounts for 0.36% of the portfolio, ranked #61.

Glenmede Trust first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $161M in Q1 2018. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Glenmede Trust held 341,137 shares of AbbVie worth $74.2M as of Q1 2026.
Glenmede Trust sold 3,885 AbbVie shares in Q1 2026, an estimated $862K.
AbbVie made up 0.36% of Glenmede Trust's portfolio in Q1 2026, its #61 holding.
Glenmede Trust first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
Glenmede Trust's AbbVie position peaked at $161M in Q1 2018.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.